Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 35Lymphoma 10Leukemia, B-Cell 10Leukemia 9Recurrence 8Lymphoma, Non-Hodgkin 7Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Follicular 6Neoplasms 5Bronchiolitis Obliterans Syndrome 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Mantle-Cell 3Lymphoma, B-Cell 2Hodgkin Disease 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Thrombocytopenia 1Paraproteinemias 1Oncology Patients Receiving Chemotherapy 1Melanoma 1Lymphoma, B-Cell, Marginal Zone 1Lymphocytosis 1Lymphadenopathy 1Leukemia, Prolymphocytic 1Leukemia, Lymphoid 1Fever 1Fatigue 1Disease 1Agammaglobulinemia 1

Interventions

Rituximab 52Cyclophosphamide 42fludarabine phosphate 41Peripheral Blood Stem Cell Transplantation 41Whole-Body Irradiation 26Mycophenolic Acid 25Cyclosporine 21Bortezomib 21Dexamethasone 19Busulfan 18Tacrolimus 17Etoposide 17Filgrastim 15Antilymphocyte Serum 14Methotrexate 13Melphalan 13ibrutinib 12Radiotherapy 11Calcium Dobesilate 9Sirolimus 8Lenalidomide 8Cyclosporins 8Methylprednisolone 7Flow Cytometry 7Everolimus 7Carboplatin 7ibritumomab tiuxetan 6zanubrutinib 5fludarabine 5Transplantation 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Waldenstrom Macroglobulinemia × ofatumumab × Clear all
NCT00811733 2017-05-30

A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia

GlaxoSmithKline

Phase 2 Completed
37 enrolled 25 charts
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡